Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 2
2005 4
2006 3
2007 8
2008 5
2009 7
2010 4
2011 4
2012 6
2013 4
2014 6
2015 15
2016 9
2017 3
2018 4
2019 7
2020 3
2021 4
2022 3
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, Kouro T, Igarashi Y, Tokito T, Kato T, Kondo T, Murakami S, Usui R, Himuro H, Horaguchi S, Tsuji K, Murotani K, Ban T, Tamura T, Miyagi Y, Sasada T. Wei F, et al. J Immunother Cancer. 2023 Jul;11(7):e006788. doi: 10.1136/jitc-2023-006788. J Immunother Cancer. 2023. PMID: 37433717 Free PMC article.
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Himuro H, Nakahara Y, Igarashi Y, Kouro T, Higashijima N, Matsuo N, Murakami S, Wei F, Horaguchi S, Tsuji K, Mano Y, Saito H, Azuma K, Sasada T. Himuro H, et al. Among authors: wei f. Cancer Immunol Immunother. 2023 Aug;72(8):2829-2840. doi: 10.1007/s00262-023-03464-w. Epub 2023 May 16. Cancer Immunol Immunother. 2023. PMID: 37188764 Free PMC article.
Enhancing Mass spectrometry-based tumor immunopeptide identification: machine learning filter leveraging HLA binding affinity, aliphatic index and retention time deviation.
Wei F, Kouro T, Nakamura Y, Ueda H, Iiizumi S, Hasegawa K, Asahina Y, Kishida T, Morinaga S, Himuro H, Horaguchi S, Tsuji K, Mano Y, Nakamura N, Kawamura T, Sasada T. Wei F, et al. Comput Struct Biotechnol J. 2024 Feb 3;23:859-869. doi: 10.1016/j.csbj.2024.01.023. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38356658 Free PMC article.
Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
Qin XY, Shirakami Y, Honda M, Yeh SH, Numata K, Lai YY, Li CL, Wei F, Xu Y, Imai K, Takai K, Chuma M, Komatsu N, Furutani Y, Gailhouste L, Aikata H, Chayama K, Enomoto M, Tateishi R, Kawaguchi K, Yamashita T, Kaneko S, Nagaoka K, Tanaka M, Sasaki Y, Tanaka Y, Baba H, Miura K, Ochi S, Masaki T, Kojima S, Matsuura T, Shimizu M, Chen PJ, Moriwaki H, Suzuki H. Qin XY, et al. Among authors: wei f. Int J Cancer. 2024 Feb 21. doi: 10.1002/ijc.34893. Online ahead of print. Int J Cancer. 2024. PMID: 38380807
Falls in the community: state of the science.
Hester AL, Wei F. Hester AL, et al. Among authors: wei f. Clin Interv Aging. 2013;8:675-9. doi: 10.2147/CIA.S44996. Epub 2013 Jun 6. Clin Interv Aging. 2013. PMID: 23776331 Free PMC article.
109 results